China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
CAMBRIDGE, Mass., April 06, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 4:20 p.m. ET in New York City.
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]
